<DOC>
	<DOCNO>NCT02856542</DOCNO>
	<brief_summary>This study aim describe patient population treat evaluate treatment adherence treatment outcomes treatment scalp psoriasis Daivobet® gel Applicator 4 week .</brief_summary>
	<brief_title>Real-life Evaluation Daivobet® Gel Applicator</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Age ≥ 18 year Dermatologist general practitioner decide initiate treatment Daivobet® gel Applicator Indication within approve label France Contraindication treatment calcipotriol betamethasone dipropionate Informed consent participate study obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Psoriasis vulgaris , scalp , topical , applicator , device</keyword>
</DOC>